Company news

Korro Bio, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results

May 11, 2023

Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results

March 9, 2023

Frequency Therapeutics to Participate at Upcoming March Investor Conferences

February 26, 2023

Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

February 12, 2023

Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program

December 18, 2022

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss

December 14, 2022

Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results

November 16, 2022

Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results

November 7, 2022

Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

October 11, 2022

Frequency Therapeutics to Participate in September Investor and Medical Conferences

August 29, 2022

Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results

August 8, 2022

Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference

May 17, 2022

Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results

May 3, 2022

Frequency Therapeutics to Participate in B. Riley Securities’ Neuro & Ophthalmology Investor Conference

April 21, 2022

Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results

March 14, 2022

Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences

February 27, 2022

Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise

December 8, 2021

Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results

November 14, 2021

Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis

November 8, 2021

Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program

October 26, 2021

Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint

October 20, 2021

Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points

September 21, 2021

Frequency Therapeutics to Present at Upcoming Investor Conferences

September 7, 2021

Frequency Therapeutics Provides Business Updates and Second Quarter 2021 Financial Results

August 11, 2021

Frequency Therapeutics to Present at Upcoming Jefferies and Goldman Sachs Healthcare Investor Conferences

May 24, 2021

Frequency Therapeutics Provides Statement of Support for the Hearing Loss Association of America’s Externally-Led Patient-Focused Drug Development Meeting to Address Sensorineural Hearing Loss

May 19, 2021

Frequency Therapeutics Provides Business Updates and Reports First Quarter 2021 Financial Results

May 12, 2021

Frequency Therapeutics Expands its Clinical Development Team, Adding Expertise in Inner Ear Physiology and Translational Science

April 12, 2021

Frequency Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

April 8, 2021

Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2020 Financial Results

March 28, 2021

Frequency Therapeutics Releases New Data from Two FX-322 Clinical Studies; Plans to Advance Single-Dose Regimen

March 22, 2021

Frequency Therapeutics Announces Publication of Phase 1/2 Data Showing Hearing Improvements in Acquired Sensorineural Hearing Loss Patients Receiving FX-322

February 21, 2021

Frequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product Planning

February 7, 2021

Frequency Therapeutics Appoints Quentin McCubbin, Ph.D., as Chief Manufacturing Officer

January 18, 2021

Frequency Therapeutics to Present 2021 Business and Pipeline Overview at the 39th Annual J.P. Morgan Healthcare Conference

January 4, 2021

Frequency Therapeutics to Host Investor Event on the Potential for Restorative Treatments for Acquired Sensorineural Hearing Loss

December 17, 2020

Frequency Therapeutics Appoints Peter Pfreundschuh as Chief Financial Officer

November 30, 2020

Frequency Therapeutics Provides Business Updates and Reports Third Quarter 2020 Financial Results

November 15, 2020

Frequency Therapeutics Announces Expanded FX-322 Clinical Development Program and Upcoming Day-90 Phase 2a Analysis

October 28, 2020

Frequency Therapeutics Appoints Cynthia Feldmann to its Board of Directors

September 24, 2020

Frequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss

September 21, 2020

Frequency Therapeutics Presents Results Demonstrating Sustained Improvement in Hearing Loss Patients Treated with FX-322

September 12, 2020

Frequency Therapeutics to Present at Upcoming Investor Conferences and Medical Meetings

September 7, 2020

Frequency Therapeutics Provides Business Updates and Reports Second Quarter 2020 Financial Results

August 11, 2020

Frequency Therapeutics Announces $42 Million Private Placement

July 16, 2020

Frequency Therapeutics Shares Clinical Data From Exploratory Study Confirming Delivery of FX-322 to the Cochlea

May 13, 2020

Frequency Therapeutics Provides Business Updates and Reports First Quarter 2020 Financial Results

May 13, 2020

Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2019 Financial Results

March 25, 2020

Frequency Therapeutics to Present at the 40th Annual Cowen Healthcare Conference

February 20, 2020

← Newer news releases · Older news releases →

Decks

The 5 newest of 6 decks. Every deck is listed under its year.